ADL Amdl,

TUSTIN, Calif., Nov. 6 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), announced today that its wholly owned subsidiary Jiangxi Jade Biochemistry, Ltd. (JJB) has executed a Memorandum of Understanding (MOU) with Jiangxi Baikang Medicine Co., Ltd. (JMB) for a distribution arrangement that it is anticipated will provide significantly expanded product distribution in China for various existing and to-be-developed JJB products. Both companies are headquartered in Jiangxi Province. JMB, a Chinese pharmaceutical company and drug distributor founded in 2004, has varied operations in the distribution of ready-made Chinese medicines, chemicals and medical raw materials, medical preparations, anti-biological preparations, chemical medicines, biochemical medicines and biological products. Both JJB and JMB entered into the MOU in order to achieve a broader-based and more profitable business for both parties. This cooperation is anticipated to include sales and distribution agreements, manufacturing agreements, and licensing agreements including the possible acquisition of JMB by JJB. As part of the initial phase of the cooperation, the parties will negotiate a mutually beneficial Product Licensing Agreement (PLA) in which JMB agrees to transfer its four new drugs (including Marine and Sodium Chloride Injection, Lomefloxacin Aspartate Injection, Lysine Hydrochloride and Glucose Injection, Omeprazole Sodium for Injection) and two generic medicine (including Roxithromycin capsule and Levofloxacin capsule) production licenses and manufacturing registration numbers to JJB. "This Partnership, when completed, is expected to significantly expand JJB's product offerings and their distribution reach within China. We are very excited about this new business development partnership, and we will work to finalize the key objectives noted in the MOU," said Gary Dreher, AMDL CEO. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc. is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its additional products can be obtained at http://www.amdl.com/ . Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright